Rob Bazemore Appointed to Akari Therapeutics Board of Directors Page 1

BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the appointment of Rob Bazemore, an experienced life sciences leader, to Akari’s Board of Directors, effective September 17, 2024.

“I am honored to have the opportunity to work with this distinguished board of directors to enhance the portfolio capabilities,” said Mr. Bazemore. “By focusing on Akari’s new lead asset, nomacopan, and on Peak’s innovative antibody-drug conjugate (ADC) platform in oncology, we can create significant value for both patients and shareholders.”